Reviews/Psoriasis Psoriatic Arthritis/Guselkumab ACR20 in biologic-naive psoriatic arthritis
Psa PJT · PSA-PJT-03 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The claim says guselkumab helps about 60% of biologic-naive psoriatic arthritis patients reach a standard 20% improvement benchmark, and the evidence supports it. The trial built specifically for previously-untreated patients [1] found 64% of patients responded on both dosing schedules, and a pooled analysis [3] found 60-62%. A second trial [2] that mixed in patients who had already tried other biologics reported somewhat lower rates of 52-59%. All of these figures come from the same family of studies (the DISCOVER program) run by a single sponsor, so there is no independent confirmation from an outside group. The panel judged the claim well supported by data designed for exactly this patient group, holding back only because the cleanest number sits at the top of the '~60%' range and everything traces to one research program.
The dedicated biologic-naive phase 3 trial [1] reports ACR20 of 64% in both the every-4-week and every-8-week arms at week 24, versus 33% on placebo. Pooled primary data across both DISCOVER trials [3] reports 62% and 60% for the two regimens. DISCOVER-1 [2], a mixed population where roughly a third had prior TNF-inhibitor exposure, is lower at 59% and 52%. Long-term DISCOVER-2 data [4] shows biologic-naive ACR20 rising to 68-76% by week 100. The cleanly biologic-naive figures cluster at 60-64%, bracketing the claim's 'approximately 60%'. The contested point: The division is whether 'approximately 60%' best represents the data when the purest biologic-naive figure [1] is 64%, at the upper edge rather than the centre of that range. A second point is which figures even count as biologic-naive: [2] and [3] include TNF-experienced patients, so only [1] and [4] are cleanly on-population.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The 52-62% figures in [2] and [3] come from populations that include TNF-experienced patients and should not be read as biologic-naive-specific; only [1] and [4] are cleanly biologic-naive.
Evidential independence is weak: every source is the same J&J DISCOVER program, with [3] and [4] re-analysing the datasets of [1] and [2]; there is no external replication.
Where it remains uncertain. Every figure originates from the single DISCOVER program with no external replication, and the cleanest biologic-naive number [1] is 64%, at the top of the '~60%' range.
Aleatory
Reported ACR20 ranges from 52% to 64% across regimens and populations [1][2][3], reflecting sampling variation around a central estimate.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Purely biologic-naive phase 3 RCT: 64% ACR20 in both arms, directly supporting an approximately 60% response.
“Significantly greater proportions of patients in the guselkumab every 4 weeks group (156 [64%] of 245) and every 8 weeks group (159 [64%] of 248) than in the placebo group (81 [33%] of 246) achieved an ACR20 response at week 24 (both p<0.0001).”
Panel auditInternal validity: high · scope of inference: Biologic-naive patients with active psoriatic arthritis, ACR20 at week 24.Key limitations: single trial · week 24 timepoint only in abstract
Pooled primary data corroborates a 60-62% ACR20 rate, though population includes some TNF-experienced patients.
“At week 24, 62% and 60% of guselkumab Q4W-treated and Q8W-treated patients pooled across DISCOVER-1 and DISCOVER-2 achieved ACR20 versus 29% of placebo-treated patients.”
Panel auditInternal validity: medium · scope of inference: Pooled DISCOVER-1 and DISCOVER-2 psoriatic arthritis patients, ACR20 at weeks 24 and 52.Key limitations: pooled mixed population · no denominators reported
Mixed-population trial giving 52-59%; consistent lower bound but not purely biologic-naive.
“ACR20 at week 24 was achieved by significantly greater proportions of patients in the guselkumab every 4 weeks group (76 [59%] of 128) and every 8 weeks group (66 [52%] of 127) than in the placebo group (28 [22%] of 126), both p<0.0001.”
Panel auditInternal validity: high · scope of inference: Patients with active psoriatic arthritis who were biologic-naive or had prior TNF-inhibitor treatment, ACR20 at week 24.Key limitations: mixed prior-treatment population · no biologic-naive subgroup rate in abstract
Confirms biologic-naive population and durability; response rises above 60% at later timepoints.
“At week 100, amelioration was durable through 2 years: ACR20 response (68-76%)”
Panel auditInternal validity: medium · scope of inference: Biologic-naive psoriatic arthritis patients, durability of ACR20 through week 100.Key limitations: week 100 not primary endpoint · no denominators or comparator · range only
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple RCT and pooled primary-data sources place biologic-naive ACR20 at 60-64%, squarely supporting the claim, with only single-program provenance limiting independence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent biologic-naive replication. Every ACR20 figure comes from the single DISCOVER program, so the central estimate is unconfirmed by any outside group. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independently sponsored phase 3 or real-world registry study reporting week-24 ACR20 in a purely biologic-naive PsA cohort.
Open question: Does an independently sponsored study reproduce a ~60-64% biologic-naive ACR20 rate at week 24? Why it is still open: All corpus evidence originates from the single J&J DISCOVER program [1][2][3][4] with no external replication.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19